BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Coronary artery disease clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for coronary artery disease: 270 (164 sponsors; 36 newly posted in the last 180 days, 10 stopped in the last 180 days; 18 new-entrant sponsors). Momentum score 10.2, rank 65 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 3, Phase 1 5, Phase 2 28, Phase 3 25, Phase 4 7, N/A 202.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Novartis Pharmaceuticals NVS | 9 | P4 2, P2 1, P3 5, NA 1 | 3 | 2 |
| Amgen AMGN | 5 | P3 2, P4 2, NA 1 | 1 | 0 |
| Eli Lilly and Company LLY | 4 | P3 2, P2 1, P1 1 | 2 | 0 |
| ECRI bv | 2 | P3 1, NA 1 | 0 | 0 |
| Tasly Pharmaceutical Group Co., Ltd | 2 | P3 1, P2 1 | 1 | 1 |
| CeleCor Therapeutics | 1 | P3 1 | 0 | 0 |
| CSL Behring | 1 | P3 1 | 0 | 0 |
| Daiichi Sankyo | 1 | P3 1 | 0 | 0 |
| DalCor Pharmaceuticals | 1 | P3 1 | 0 | 0 |
| EBI Anti Sepsis BV | 1 | P3 1 | 0 | 0 |
| iVascular S.L.U. | 1 | P3 1 | 0 | 1 |
| Jiangsu vcare pharmaceutical technology co., LTD | 1 | P3 1 | 0 | 1 |
| Moleac Pte Ltd. | 1 | P3 1 | 0 | 0 |
| NewAmsterdam Pharma NAMS | 1 | P3 1 | 0 | 0 |
| Novo Nordisk A/S NVO | 1 | P3 1 | 0 | 0 |
| Pulnovo Medical (Wuxi) Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Seismic Pharmaceuticals Operations LLC | 1 | P3 1 | 0 | 0 |
| Sinotau Pharmaceutical Group | 1 | P3 1 | 0 | 0 |
| Tasly Pharmaceuticals, Inc. | 1 | P3 1 | 0 | 1 |
| Genoss Co., Ltd. | 13 | NA 13 | 0 | 1 |
| Abbott Medical Devices | 6 | NA 6 | 0 | 1 |
| CoreAalst BV | 6 | P4 1, NA 5 | 0 | 0 |
| Abiomed Inc. | 5 | NA 5 | 1 | 0 |
| Biosensors Europe SA | 5 | EARLY_P1 1, NA 4 | 1 | 0 |
| Biotronik AG | 5 | NA 5 | 0 | 1 |
Recently stopped trials
- NCT07495813 Hoffmann-La Roche - terminated: The development of RO7763505 for coronary artery disease has been discontinued. A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease
- NCT07625306 Novartis Pharmaceuticals - withdrawn: Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp
- NCT06071702 Medinol Ltd. - suspended: Study was not initiated in any site. Sponsor decided not to start the study IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
- NCT07449325 VahatiCor, Inc. - suspended: Study suspended to implement a protocol change Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)
- NCT06700720 Beijing Inno Medicine Co., Ltd. - terminated: The study was terminated at the request of the Sponsor. YN001-004 in Patients With Coronary Atherosclerosis in Australia
- NCT06139328 Boehringer Ingelheim - terminated: Sponsor decision IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
- NCT00546260 Alexion Pharmaceuticals, Inc. - terminated: Administrative reasons. Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI
- NCT04743245 TherOx - terminated: Sponsor Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
- NCT04723186 Shaanxi Micot Pharmaceutical Technology Co., Ltd. - terminated: The study was decided to be terminated due to commercial considerations,(not the safety issues of the product). MT1002 Phase II Study in ACS Patients With PCI
- NCT05325112 HeartFlow, Inc. - terminated: Sponsor decision to terminate the study Assessing Diagnostic Value of Non-invasive FFR-CT in Coronary Care in the Emergency Department
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | United Therapeutics UTHR | NCT03683186 A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseas | enrolling by invitation | 1000 |
| 2026-12 est. | P1/P2 | GE Healthcare | NCT04604782 A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients | Myocardial Ischemia; Coronary Artery Disease | recruiting | 54 |
| 2026-12 est. | P2 | Pulmovant, Inc. | NCT07333183 A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | Pulmonary Hypertension; Interstitial Lung Disease (ILD); Lung Diseases; Vascular Diseases; Cardiovas | recruiting | 20 |
| 2026-12-30 est. | P3 | Jiangsu vcare pharmaceutical technology co., LTD | NCT06577519 Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | recruiting | 1000 |
| 2026-12-30 est. | P2 | XyloCor Therapeutics, Inc. | NCT07118449 Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG | Coronary Artery Disease (CAD) | not yet recruiting | 116 |
| 2026-12-31 est. | P1/P2 | Tasly Pharmaceutical Group Co., Ltd | NCT07265349 A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure | Coronary Artery Bypass Grafting (CABG); Chronic Heart Failure; Chronic Ischemic Cardiomyopathy | recruiting | 51 |
| 2027-01-11 est. | P3 | AstraZeneca AZN | NCT07000123 A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | Cardiovascular Disease | active not recruiting | 3103 |
| 2027-01-13 est. | P3 | iVascular S.L.U. | NCT05952206 Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy | Coronary Artery Disease | active not recruiting | 2312 |
| 2027-01-16 est. | P3 | Novartis Pharmaceuticals NVS | NCT07102628 Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | Acute Coronary Syndrome | active not recruiting | 305 |
| 2027-01-29 est. | P3 | Novo Nordisk A/S NVO | NCT06118281 ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | Cardiovascular Risk; Acute Myocardial Infarction (AMI) | active not recruiting | 10000 |
| 2027-02-08 est. | P2 | Abcentra | NCT06927739 Focused Orticumab Research for Treating Inflammation in Coronary Arteries | Acute Coronary Syndromes; Coronary Arterial Disease (CAD); Inflammation; Heart Disease; Myocardial I | recruiting | 240 |
| 2027-02-14 est. | P1/P2 | Hudson Biotech | NCT07487363 TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD | Atherosclerotic Cardiovascular Diseases; Endothelial Dysfunction | recruiting | 80 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P3 | NewAmsterdam Pharma NAMS | NCT05202509 Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | Atherosclerotic Cardiovascular Disease | active not recruiting | 9541 |
| 2026-10-26 est. | P3 | Novartis Pharmaceuticals NVS | NCT05360446 Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in | Coronary Artery Disease | active not recruiting | 610 |
| 2026-10-02 | P3 | MedTrace Pharma A/S | NCT05134012 RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW) | Coronary Artery Disease | completed | 232 |
| 2026-10-01 est. | P2 | Research Institute of Geroprotective Technologies | NCT07397351 Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation | Coronary Artery Disease | recruiting | 180 |
| 2026-10 est. | P2 | Beijing Inno Medicine Co., Ltd. | NCT07311330 Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction | Atherosclerotic Cardiovascular Disease (ASCVD); Erectile Dysfunction | recruiting | 40 |
| 2026-08-01 | P1/P2 | Implicit Bioscience | NCT06678074 Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI | STEMI; STEMI (ST Elevation MI); STEMI - ST Elevation Myocardial Infarction (MI); Stent Implantation | completed | 7 |
| 2026-07-22 | P2 | Beijing Inno Medicine Co., Ltd. | NCT06700720 YN001-004 in Patients With Coronary Atherosclerosis in Australia | Coronary Artery Disease; Coronary Atherosclerotic Disease | terminated | 3 |
| 2026-07-16 | P3 | Novartis Pharmaceuticals NVS | NCT04023552 Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD | Cardiovascular Disease and Lipoprotein(a) | completed | 8323 |
| 2026-07-02 | P2 | ResoTher Pharma | NCT06465303 A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI) | ST Elevation Myocardial Infarction | completed | 66 |
| 2026-05-26 | P2 | Pulmovant, Inc. | NCT06635850 A Study of Mosliciguat in PH-ILD | Pulmonary Hypertension; Interstitial Lung Disease; Lung Diseases; Vascular Diseases; Cardiovascular | active not recruiting | 135 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "coronary artery disease"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.